This technology advances the company's products beyond the laboratory setting into clinical applications. The key aspects of the patent describe a bioreactor for Tissue Engineered Medical Products (TEMPs) that measures the response of the TEMP to mechanical and environmental stimulations. Based upon the measurements, the bioreactor is able to alter the stimulation regimen utilizing program algorithms. "This is a very significant advancement in the state of this industry because it paves the way for bioreactors that can automatically culture and grow Tissue Engineered Medical Products from the seeded scaffold to a final replacement graft." said Kent Vilendrer, Company founder and CEO. "Up until now bioreactors have been fixed level devices… meaning a mechanical or environmental stimulation regimen is input to the device and the growth response is observed much later, oftentimes after the experiment has been completed.   With this new technology, the TEMP response is measured continuously and the mechanical and environmental stimulation profiles are altered via computer control according to a “recipe” that has been established by the researcher. Applicable to ligaments, tendons, cartilage, bone, skin and vascular grafts this technology ushers in a new era in tissue engineering."